Skip to main content
main-content
Erschienen in: Forensische Psychiatrie, Psychologie, Kriminologie 3/2019

15.05.2019 | Schizophrenie | Übersicht

Cannabis und Schizophrenie – Risikofaktoren, diagnostische Einordnung und Auswirkungen auf Verlauf und Prognose

verfasst von: PD Dr. med. Patrik Roser

Erschienen in: Forensische Psychiatrie, Psychologie, Kriminologie | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Schizophrene Psychosen sind häufig mit dem Konsum von Cannabis assoziiert. Die vorliegende Übersichtsarbeit beschäftigt sich zunächst mit der Frage nach einem möglichen kausalen Zusammenhang zwischen dem Konsum von Cannabis und der Entwicklung einer Schizophrenie. Epidemiologische Studien konnten hierbei den Konsum von Cannabis übereinstimmend als relevanten Risikofaktor identifizieren. Für das Ausmaß des Erkrankungsrisikos scheint insbesondere die Interaktion von Cannabis mit weiteren Risikofaktoren (genetische Vulnerabilität, traumatische Erfahrungen in der Kindheit, Zusammensetzung und Potenz der konsumierten Cannabiszubereitungen) entscheidend zu sein. Im nachfolgenden Kapitel werden die verschiedenen cannabisassoziierten psychotischen Zustandsbilder eingehender beschrieben und nach zeitlichem Auftreten, Dauer und klinischer Relevanz voneinander abgegrenzt sowie anhand der Kriterien der ICD-10 diagnostisch eingeordnet. Abschließend werden die Auswirkungen des Cannabiskonsums auf die Psychopathologie, das psychosoziale Funktionsniveau, das psychotische Rückfallrisiko und die Behandlungsadhärenz bei Patienten mit einer schizophrenen Psychose und der positive Einfluss anhaltender Abstinenz auf den klinischen Verlauf näher dargestellt.
Literatur
Zurück zum Zitat van Amsterdam J, Brunt T, van den Brink W (2015) The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. J Psychopharmacol (Oxf) 29:254–263 CrossRef van Amsterdam J, Brunt T, van den Brink W (2015) The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. J Psychopharmacol (Oxf) 29:254–263 CrossRef
Zurück zum Zitat Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE (2002) Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 325:1212–1213 CrossRefPubMedPubMedCentral Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE (2002) Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 325:1212–1213 CrossRefPubMedPubMedCentral
Zurück zum Zitat Baeza I, Graell M, Moreno D, Castro-Fornieles J, Parellada M, González-Pinto A et al (2009) Cannabis use in children and adolescents with first episode psychosis: influence on psychopathology and short-term outcome (CAFEPS study). Schizophr Res 113:129–137 CrossRefPubMed Baeza I, Graell M, Moreno D, Castro-Fornieles J, Parellada M, González-Pinto A et al (2009) Cannabis use in children and adolescents with first episode psychosis: influence on psychopathology and short-term outcome (CAFEPS study). Schizophr Res 113:129–137 CrossRefPubMed
Zurück zum Zitat Bagot KS, Milin R, Kaminer Y (2015) Adolescent initiation of cannabis use and early-onset psychosis. Subst Abus 36:524–533 CrossRefPubMed Bagot KS, Milin R, Kaminer Y (2015) Adolescent initiation of cannabis use and early-onset psychosis. Subst Abus 36:524–533 CrossRefPubMed
Zurück zum Zitat Barbeito S, Vega P, Ruiz de Azúa S, Saenz M, Martinez-Cengotitabengoa M, González-Ortega I (2013) Cannabis use and involuntary admission may mediate long-term adherence in first-episode psychosis patients: a prospective longitudinal study. BMC Psychiatry 13:326 CrossRefPubMedPubMedCentral Barbeito S, Vega P, Ruiz de Azúa S, Saenz M, Martinez-Cengotitabengoa M, González-Ortega I (2013) Cannabis use and involuntary admission may mediate long-term adherence in first-episode psychosis patients: a prospective longitudinal study. BMC Psychiatry 13:326 CrossRefPubMedPubMedCentral
Zurück zum Zitat Benyamina A, Karila L, Lafaye G, Blecha L (2016) Genetic influences in cannabis use disorders and psychosis: dopamine and beyond. Curr Pharm Des 22:6392–6396 CrossRefPubMed Benyamina A, Karila L, Lafaye G, Blecha L (2016) Genetic influences in cannabis use disorders and psychosis: dopamine and beyond. Curr Pharm Des 22:6392–6396 CrossRefPubMed
Zurück zum Zitat Boydell J, Dean K, Dutta R, Giouroukou E, Fearon P, Murray R (2007) A comparison of symptoms and family history in schizophrenia with and without prior cannabis use: implications for the concept of cannabis psychosis. Schizophr Res 93:203–210 CrossRefPubMed Boydell J, Dean K, Dutta R, Giouroukou E, Fearon P, Murray R (2007) A comparison of symptoms and family history in schizophrenia with and without prior cannabis use: implications for the concept of cannabis psychosis. Schizophr Res 93:203–210 CrossRefPubMed
Zurück zum Zitat Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H et al (2005) Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 57:1117–1127 CrossRefPubMed Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H et al (2005) Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 57:1117–1127 CrossRefPubMed
Zurück zum Zitat Clausen L, Hjorthoj CR, Thorup A, Jeppesen P, Petersen L, Bertelsen M, Nordentoft M (2014) Change in cannabis use, clinical symptoms and social functioning among patients with first-episode psychosis: a 5-year follow-up study of patients in the OPUS trial. Psychol Med 44:117–126 CrossRefPubMed Clausen L, Hjorthoj CR, Thorup A, Jeppesen P, Petersen L, Bertelsen M, Nordentoft M (2014) Change in cannabis use, clinical symptoms and social functioning among patients with first-episode psychosis: a 5-year follow-up study of patients in the OPUS trial. Psychol Med 44:117–126 CrossRefPubMed
Zurück zum Zitat Coldham EL, Addington J, Addington D (2002) Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 106:286–290 CrossRefPubMed Coldham EL, Addington J, Addington D (2002) Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 106:286–290 CrossRefPubMed
Zurück zum Zitat Colizzi M, Iyegbe C, Powell J, Ursini G, Porcelli A, Bonvino A et al (2015a) Interaction between functional genetic variation of DRD2 and cannabis use on risk of psychosis. Schizophr Bull 41:1171–1182 CrossRefPubMedPubMedCentral Colizzi M, Iyegbe C, Powell J, Ursini G, Porcelli A, Bonvino A et al (2015a) Interaction between functional genetic variation of DRD2 and cannabis use on risk of psychosis. Schizophr Bull 41:1171–1182 CrossRefPubMedPubMedCentral
Zurück zum Zitat Colizzi M, Iyegbe C, Powell J, Blasi G, Bertolino A, Murray RM, Di Forti M (2015b) Interaction between DRD2 and AKT1 genetic variations on risk of psychosis in cannabis users: a case-control study. Npj Schizophr 1:15025 CrossRefPubMedPubMedCentral Colizzi M, Iyegbe C, Powell J, Blasi G, Bertolino A, Murray RM, Di Forti M (2015b) Interaction between DRD2 and AKT1 genetic variations on risk of psychosis in cannabis users: a case-control study. Npj Schizophr 1:15025 CrossRefPubMedPubMedCentral
Zurück zum Zitat Colizzi M, McGuire P, Pertwee RG, Bhattacharyya S (2016) Effects of cannabis on glutamate signalling in the brain: a systematic review of human and animal evidence. Neurosci Biobehav Rev 64:359–381 CrossRefPubMed Colizzi M, McGuire P, Pertwee RG, Bhattacharyya S (2016) Effects of cannabis on glutamate signalling in the brain: a systematic review of human and animal evidence. Neurosci Biobehav Rev 64:359–381 CrossRefPubMed
Zurück zum Zitat Dekker N, Linszen DH, De Haan L (2009) Reasons for cannabis use and effects of cannabis use as reported by patients with psychotic disorders. Psychopathology 42:350–360 CrossRefPubMed Dekker N, Linszen DH, De Haan L (2009) Reasons for cannabis use and effects of cannabis use as reported by patients with psychotic disorders. Psychopathology 42:350–360 CrossRefPubMed
Zurück zum Zitat Dilling H, Mombour W, Schmidt MH (2015) ICD-10 Internationale Klassifikation psychischer Störungen, 10. Aufl. Hogrefe, Bern Dilling H, Mombour W, Schmidt MH (2015) ICD-10 Internationale Klassifikation psychischer Störungen, 10. Aufl. Hogrefe, Bern
Zurück zum Zitat D’Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT et al (2004) The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychoparmacology 29:1558–1572 CrossRef D’Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT et al (2004) The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychoparmacology 29:1558–1572 CrossRef
Zurück zum Zitat D’Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G et al (2005) Delta-9-tetrahydrocannabinol effects in schizophrenia: implication for cognition, psychosis, and addiction. Biol Psychiatry 57:594–608 CrossRefPubMed D’Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G et al (2005) Delta-9-tetrahydrocannabinol effects in schizophrenia: implication for cognition, psychosis, and addiction. Biol Psychiatry 57:594–608 CrossRefPubMed
Zurück zum Zitat Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR et al (2009) High-potency cannabis and the risk of psychosis. Br J Psychiatry 195:488–491 CrossRefPubMedPubMedCentral Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR et al (2009) High-potency cannabis and the risk of psychosis. Br J Psychiatry 195:488–491 CrossRefPubMedPubMedCentral
Zurück zum Zitat Di Forti M, Iyegbe C, Sallis H, Kolliakou A, Falcone MA, Paparelli A et al (2012) Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol Psychiatry 72:811–816 CrossRefPubMed Di Forti M, Iyegbe C, Sallis H, Kolliakou A, Falcone MA, Paparelli A et al (2012) Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol Psychiatry 72:811–816 CrossRefPubMed
Zurück zum Zitat Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA et al (2014) Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull 40:1509–1517 CrossRefPubMed Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA et al (2014) Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull 40:1509–1517 CrossRefPubMed
Zurück zum Zitat Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M et al (2015) Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry 2:233–238 CrossRefPubMed Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M et al (2015) Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry 2:233–238 CrossRefPubMed
Zurück zum Zitat ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC (2016) Changes in cannabis potency over the last 2 decades (1995–2014): analysis of current data in the United States. Biol Psychiatry 79:613–619 CrossRefPubMedPubMedCentral ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC (2016) Changes in cannabis potency over the last 2 decades (1995–2014): analysis of current data in the United States. Biol Psychiatry 79:613–619 CrossRefPubMedPubMedCentral
Zurück zum Zitat Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S et al (2013) Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol (Oxf) 27:19–27 CrossRef Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S et al (2013) Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol (Oxf) 27:19–27 CrossRef
Zurück zum Zitat Fantegrossi WE, Wilson CD, Berquist MD (2018) Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin, and glutamate systems. Drug Metab Rev 50:65–73 CrossRefPubMedPubMedCentral Fantegrossi WE, Wilson CD, Berquist MD (2018) Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin, and glutamate systems. Drug Metab Rev 50:65–73 CrossRefPubMedPubMedCentral
Zurück zum Zitat Gage SH, Hickman M, Zammit S (2016) Association between cannabis and psychosis: epidemiologic evidence. Biol Psychiatry 79:549–556 CrossRefPubMed Gage SH, Hickman M, Zammit S (2016) Association between cannabis and psychosis: epidemiologic evidence. Biol Psychiatry 79:549–556 CrossRefPubMed
Zurück zum Zitat Henquet C, Di Forti M, Morrison P, Kuepper R, Murray RM (2008) Gene-environment interplay between cannabis and psychosis. Schizophr Bull 34:1111–1121 CrossRefPubMedPubMedCentral Henquet C, Di Forti M, Morrison P, Kuepper R, Murray RM (2008) Gene-environment interplay between cannabis and psychosis. Schizophr Bull 34:1111–1121 CrossRefPubMedPubMedCentral
Zurück zum Zitat Houston JE, Murphy J, Adamson G, Stringer M, Shevlin M (2008) Childhood sexual abuse, early cannabis use, and psychosis: testing an interaction model based on the National Comorbidity Survey. Schizophr Bull 34:580–585 CrossRefPubMed Houston JE, Murphy J, Adamson G, Stringer M, Shevlin M (2008) Childhood sexual abuse, early cannabis use, and psychosis: testing an interaction model based on the National Comorbidity Survey. Schizophr Bull 34:580–585 CrossRefPubMed
Zurück zum Zitat Houston JE, Murphy J, Shevlin M, Adamson G (2011) Cannabis use and psychosis: re-visiting the role of childhood trauma. Psychol Med 41:2339–2348 CrossRefPubMed Houston JE, Murphy J, Shevlin M, Adamson G (2011) Cannabis use and psychosis: re-visiting the role of childhood trauma. Psychol Med 41:2339–2348 CrossRefPubMed
Zurück zum Zitat Iseger TA, Bossong MG (2015) A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res 162:153–161 CrossRefPubMed Iseger TA, Bossong MG (2015) A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res 162:153–161 CrossRefPubMed
Zurück zum Zitat Koskinen J, Löhönen J, Koponen H, Isohanni M, Miettunen J (2010) Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull 36:1115–1130 CrossRefPubMed Koskinen J, Löhönen J, Koponen H, Isohanni M, Miettunen J (2010) Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull 36:1115–1130 CrossRefPubMed
Zurück zum Zitat Kuepper R, Morrison PD, van Os J, Murray RM, Kenis G, Henquet C (2010) Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines. Schizophr Res 121:107–117 CrossRefPubMed Kuepper R, Morrison PD, van Os J, Murray RM, Kenis G, Henquet C (2010) Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines. Schizophr Res 121:107–117 CrossRefPubMed
Zurück zum Zitat Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV (2002) Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 63:892–909 CrossRefPubMed Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV (2002) Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 63:892–909 CrossRefPubMed
Zurück zum Zitat Linszen DH, Dingemans PM, Lenior ME (1994) Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 51:273–279 CrossRefPubMed Linszen DH, Dingemans PM, Lenior ME (1994) Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 51:273–279 CrossRefPubMed
Zurück zum Zitat Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E (2016) Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull 42:1262–1269 CrossRefPubMedPubMedCentral Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E (2016) Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull 42:1262–1269 CrossRefPubMedPubMedCentral
Zurück zum Zitat van der Meer FJ, Velthorst E, Genetic Risk and Outcome of Psychosis (GROUP) Investigators (2015) Course of cannabis use and clinical outcome in patients with non-affective psychosis: a 3-year follow-up study. Psychol Med 45:1977–1988 CrossRefPubMed van der Meer FJ, Velthorst E, Genetic Risk and Outcome of Psychosis (GROUP) Investigators (2015) Course of cannabis use and clinical outcome in patients with non-affective psychosis: a 3-year follow-up study. Psychol Med 45:1977–1988 CrossRefPubMed
Zurück zum Zitat Mehmedic Z, Chandra S, Slade D, Denham H, Foster S, Patel AS et al (2010) Potency trends of ∆9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci 55:1209–1217 CrossRefPubMed Mehmedic Z, Chandra S, Slade D, Denham H, Foster S, Patel AS et al (2010) Potency trends of ∆9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci 55:1209–1217 CrossRefPubMed
Zurück zum Zitat Miller R, Ream G, McCormack J, Gunduz-Bruce H, Sevy S, Robinson D (2009) A prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia. Schizophr Res 113:138–144 CrossRefPubMedPubMedCentral Miller R, Ream G, McCormack J, Gunduz-Bruce H, Sevy S, Robinson D (2009) A prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia. Schizophr Res 113:138–144 CrossRefPubMedPubMedCentral
Zurück zum Zitat Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370:319–328 CrossRef Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370:319–328 CrossRef
Zurück zum Zitat Moulin V, Baumann P, Gholamrezaee M, Alameda L, Palix J, Gasser J, Conus P (2018) Cannabis, a significant risk factor for violent behavior in the early phase psychosis. Two patterns of interaction of factors increase the risk of violent behavior: cannabis use disorder and impulsivity; cannabis use disorder, lack of insight and treatment adherence. Front Psychiatry 9:294 CrossRefPubMedPubMedCentral Moulin V, Baumann P, Gholamrezaee M, Alameda L, Palix J, Gasser J, Conus P (2018) Cannabis, a significant risk factor for violent behavior in the early phase psychosis. Two patterns of interaction of factors increase the risk of violent behavior: cannabis use disorder and impulsivity; cannabis use disorder, lack of insight and treatment adherence. Front Psychiatry 9:294 CrossRefPubMedPubMedCentral
Zurück zum Zitat Murphy J, Houston JE, Shevlin M, Adamson G (2013) Childhood sexual trauma, cannabis use and psychosis: statistically controlling for pre-trauma psychosis and psychopathology. Soc Psychiatry Psychiatr Epidemiol 48:853–861 CrossRefPubMed Murphy J, Houston JE, Shevlin M, Adamson G (2013) Childhood sexual trauma, cannabis use and psychosis: statistically controlling for pre-trauma psychosis and psychopathology. Soc Psychiatry Psychiatr Epidemiol 48:853–861 CrossRefPubMed
Zurück zum Zitat Pelayo-Terán JM, Diaz FJ, Pérez-Iglesias R, Suárez-Pinilla P, Tabarés-Seisdedos R, de León J, Crespo-Facorro B (2014) Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis. Psychol Med 44:37–50 CrossRefPubMed Pelayo-Terán JM, Diaz FJ, Pérez-Iglesias R, Suárez-Pinilla P, Tabarés-Seisdedos R, de León J, Crespo-Facorro B (2014) Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis. Psychol Med 44:37–50 CrossRefPubMed
Zurück zum Zitat Rabin RA, Kozak K, Zakzanis KK, Remington G, George TP (2018) Effects of extended cannabis abstinence on clinical symptoms in cannabis dependent schizophrenia patients versus non-psychiatric controls. Schizophr Res 194:55–61 CrossRefPubMed Rabin RA, Kozak K, Zakzanis KK, Remington G, George TP (2018) Effects of extended cannabis abstinence on clinical symptoms in cannabis dependent schizophrenia patients versus non-psychiatric controls. Schizophr Res 194:55–61 CrossRefPubMed
Zurück zum Zitat Ranganathan M, Skosnik PD, D’Souza DC (2016) Marijuana and madness: associations between cannabinoids and psychosis. Biol Psychiatry 79:511–513 CrossRefPubMed Ranganathan M, Skosnik PD, D’Souza DC (2016) Marijuana and madness: associations between cannabinoids and psychosis. Biol Psychiatry 79:511–513 CrossRefPubMed
Zurück zum Zitat Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK (1990) Comorbidity of mental disorders with alcohol and other drug abuse. JAMA 264:2511–2518 CrossRefPubMed Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK (1990) Comorbidity of mental disorders with alcohol and other drug abuse. JAMA 264:2511–2518 CrossRefPubMed
Zurück zum Zitat Robinson DG, Woerner MG, Alvir JM, Geisler S, Koreen A, Sheitmen B et al (1999) Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 156:544–549 CrossRefPubMed Robinson DG, Woerner MG, Alvir JM, Geisler S, Koreen A, Sheitmen B et al (1999) Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 156:544–549 CrossRefPubMed
Zurück zum Zitat Roser P, Haussleiter IS (2012) Antipsychotic-like effects of cannabidiol and rimonabant: systematic review of animal and human studies. Curr Pharm Des 18:5141–5155 CrossRefPubMed Roser P, Haussleiter IS (2012) Antipsychotic-like effects of cannabidiol and rimonabant: systematic review of animal and human studies. Curr Pharm Des 18:5141–5155 CrossRefPubMed
Zurück zum Zitat Schoeler T, Monk A, Sami MB, Klamerus E, Foglia E, Brown R et al (2016a) Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. Lancet Psychiatry 3:215–225 CrossRefPubMed Schoeler T, Monk A, Sami MB, Klamerus E, Foglia E, Brown R et al (2016a) Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. Lancet Psychiatry 3:215–225 CrossRefPubMed
Zurück zum Zitat Schoeler T, Petros N, Di Forti M, Klamerus E, Foglia E, Ajnakina O et al (2016b) Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study. Lancet Psychiatry 3:947–953 CrossRefPubMed Schoeler T, Petros N, Di Forti M, Klamerus E, Foglia E, Ajnakina O et al (2016b) Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study. Lancet Psychiatry 3:947–953 CrossRefPubMed
Zurück zum Zitat Schoeler T, Petros N, Di Forti M, Klamerus E, Foglia E, Murray R, Bhattacharyya S (2017) Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective study. Lancet Psychiatry 4:627–633 CrossRefPubMedPubMedCentral Schoeler T, Petros N, Di Forti M, Klamerus E, Foglia E, Murray R, Bhattacharyya S (2017) Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective study. Lancet Psychiatry 4:627–633 CrossRefPubMedPubMedCentral
Zurück zum Zitat Sideli L, Fisher HL, Murray RM, Sallis H, Russo M, Stilo SA et al (2018) Interaction between cannabis consumption and childhood abuse in psychotic disorders: preliminary findings on the role of different patterns of cannabis use. Early Interv Psychiatry 12:135–142 CrossRefPubMed Sideli L, Fisher HL, Murray RM, Sallis H, Russo M, Stilo SA et al (2018) Interaction between cannabis consumption and childhood abuse in psychotic disorders: preliminary findings on the role of different patterns of cannabis use. Early Interv Psychiatry 12:135–142 CrossRefPubMed
Zurück zum Zitat Täschner KL (2005) Psychosen bei Cannabiskonsum. In: Täschner KL (Hrsg) Cannabis – Biologie, Konsum und Wirkung, 4. Aufl. Deutscher Ärzte-Verlag, Köln, S 193–246 Täschner KL (2005) Psychosen bei Cannabiskonsum. In: Täschner KL (Hrsg) Cannabis – Biologie, Konsum und Wirkung, 4. Aufl. Deutscher Ärzte-Verlag, Köln, S 193–246
Zurück zum Zitat Varese F, Smeets F, Drukker M, Lieverse R, Lataster T, Viechtbauer W et al (2012) Childhood adversities increase the risk of psychosis: a meta-analysis of patient-control, prospective- and cross-sectional cohort studies. Schizophr Bull 38:661–671 CrossRefPubMedPubMedCentral Varese F, Smeets F, Drukker M, Lieverse R, Lataster T, Viechtbauer W et al (2012) Childhood adversities increase the risk of psychosis: a meta-analysis of patient-control, prospective- and cross-sectional cohort studies. Schizophr Bull 38:661–671 CrossRefPubMedPubMedCentral
Zurück zum Zitat van Winkel R, Genetic Risk and Outcome of Psychosis (GROUP) Investigators (2011) Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. Arch Gen Psychiatry 68:148–157 CrossRefPubMed van Winkel R, Genetic Risk and Outcome of Psychosis (GROUP) Investigators (2011) Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. Arch Gen Psychiatry 68:148–157 CrossRefPubMed
Metadaten
Titel
Cannabis und Schizophrenie – Risikofaktoren, diagnostische Einordnung und Auswirkungen auf Verlauf und Prognose
verfasst von
PD Dr. med. Patrik Roser
Publikationsdatum
15.05.2019
Verlag
Springer Berlin Heidelberg
Schlagwort
Schizophrenie
Erschienen in
Forensische Psychiatrie, Psychologie, Kriminologie / Ausgabe 3/2019
Print ISSN: 1862-7072
Elektronische ISSN: 1862-7080
DOI
https://doi.org/10.1007/s11757-019-00543-6

Weitere Artikel der Ausgabe 3/2019

Forensische Psychiatrie, Psychologie, Kriminologie 3/2019 Zur Ausgabe

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Psychiatrie und bleiben Sie gut informiert – ganz bequem per eMail.